MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
5.26
+0.06
+1.15%
Closed 18:14 03/12 EDT
OPEN
5.25
PREV CLOSE
5.20
HIGH
5.44
LOW
5.10
VOLUME
283.96K
TURNOVER
--
52 WEEK HIGH
17.94
52 WEEK LOW
4.740
MARKET CAP
114.53M
P/E (TTM)
-2.0791
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AARD last week (0302-0306)?
Weekly Report · 3d ago
A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves
Simply Wall St · 03/05 21:36
Schall Law Firm Investigates Aardvark Therapeutics for Securities Law Violations
Reuters · 03/04 15:21
What's Going On With Aardvark Therapeutics Stock On Wednesday?
Benzinga · 03/04 13:54
Pomerantz Law Firm Probes Aardvark Therapeutics for Potential Securities Fraud
Reuters · 03/03 22:28
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Benzinga · 03/03 13:39
Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101
Simply Wall St · 03/03 12:22
Morning News Wrap-Up 3/2/26: Monday’s Biggest Stock Market Stories!
TipRanks · 03/02 18:00
More
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.